SEC Tracker
Get the app

BioXcel Therapeutics

BTAIQ

4 months of cash as of Jun 30, 2026 from the 10-Q on EDGAR

Get email alertsGet the app
Legal name
BioXcel Therapeutics, Inc.
CIK
1720893
Sector
Biotech and pharma

Latest Revenue $182K (+52%), diluted EPS −$0.49 in the quarter ended Jun 30, 2026, from a 10-Q filed .

Insiders No open-market insider buys or sells at BioXcel Therapeutics in the last 90 days; 2 filings reported awards, option exercises, tax withholding or new insiders. Every trade

Major8-K filed

BioXcel Therapeutics sold assets to Teva

  • Completed sale of neuroscience assets to Teva for $57.5M upfront
  • Teva to pay up to $67.5M in development milestones for IGALMI®
  • Key executives terminated as part of wind-down

Read the 8-K on EDGARTables over time

Cash runway and key numbers

About 1.4 quarters of cash at the average operating burn of the last 2 quarters, which would last to about Nov 2026.

Cash
$12.8M
Operating burn a quarter, average of the last 2 quarters
$9.0M

From the 10-Q 0001104659-26-095965 for the period ended Jun 30, 2026, as tagged in its XBRL. An estimate from reported figures, not a forecast or advice.

Every line item over time, with Excel and CSV export

Get an email when BioXcel Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What BioXcel Therapeutics does

Products

  • IGALMI In development

    IGALMI is an orally dissolving sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Source

    Key ingredient: dexmedetomidine · Segment: Neuroscience

    • Food and Drug Administration (FDA): approved Source

  • BXCL501 In development

    BXCL501 is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. Source

    Key ingredient: dexmedetomidine · Segment: Neuroscience

    • Food and Drug Administration (FDA): investigational, Investigational New Drug (IND) Source

  • BXCL701 In development

    BXCL701 is an investigational oral innate immune activator from OnkosXcel Therapeutics as a potential therapy for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. Source

    Key ingredient: oral innate immune activator · Segment: Immuno-oncology

    • FDA: investigational, Investigational New Drug Source
Employees
The company reduced its workforce by approximately 15% in May 2024 and an additional 28% in September 2024. Source

From the 10-K filed Mar 27, 2026, Item 1, Business (its first part). Open the filing. Each line links to the passage it restates. The company's own description, summarized; not investment advice.

All filings

Results, 8-Ks and Major or Notable filings come first, then registrations and share actions, then everything else, newest first. Routine filings are kept here unmarked; insider filings are summed up in one line.

Results, 8-Ks and key filings

  3. 3 more 8-K filings, Aug 28 to Aug 24
  6. 3 more 8-K filings, Aug 3 to May 15
  11. 4 more 8-K filings, Mar 11 to Jan 20

    1. Financing: agreement (8-K) with a 424B5 prospectus filed the same day. 424B5 on EDGAR

No open-market insider buys or sells at BioXcel Therapeutics in the last 90 days; 2 filings reported awards, option exercises, tax withholding or new insiders. Every BTAIQ insider trade

Financing and share filings

Other filings

Older filings on EDGAR

Listing compliance

0 open of 1 listing notice from 8-K item 3.01.

  • Sep 1, 2026 8-K item 3.01 notice; rule and cure date not stated, see the filing

Dates and rules are as stated in each 8-K item 3.01 filing; a blank means the filing did not state one. Read the filing for the full terms. All open notices

Trading halts

No trading halts for BTAIQ since Feb 22, 2019, when SEC Tracker began reading the Nasdaq Trader feed.

Halt times and codes from the Nasdaq Trader trade halts feed, which lists Nasdaq and other exchange halts. Filings matched by SEC Tracker from EDGAR by company and time. Not investment advice. All recent halts

Coming up

  1. Earnings, expected
  2. 10-Q, expected (deadline Nov 16)

Stated dates are as each filing on EDGAR gives them; an expected date is estimated from the company's past filing dates, the same estimate as the top of the page. Not investment advice.

BioXcel Therapeutics shares and listing

From the company's own filings; each row names its source. Not investment advice.

  • Shares outstandingas of Aug 11, 2026 (10-Q filed Aug 13)31.3Mwarrants, notes and options not read yet, so fully diluted is not known
  • Listing compliance8-K item 3.011 noticestatus not stated, see the filings

Insider activity

No open-market insider buys or sells at BioXcel Therapeutics in the last 90 days; 2 filings reported awards, option exercises, tax withholding or new insiders.

All BTAIQ insider trades